Detalhe da pesquisa
1.
A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma.
Mutagenesis;
2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38606763
2.
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials.
ESMO Open;
9(3): 102941, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452437
3.
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
Cancer Med;
12(8): 9392-9400, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36880426
4.
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
ESMO Open;
8(1): 100777, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36731325
5.
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
ESMO Open;
7(5): 100575, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36152486
6.
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
ESMO Open;
7(5): 100567, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35994791
7.
Ultrasound-guided fine needle aspiration biopsy (FNAB) demonstrating upper distal extremity metastasis of lung adenocarcinoma: a case report and review of the literature.
Eur Rev Med Pharmacol Sci;
25(8): 3221-3225, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33928607
8.
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.
ESMO Open;
6(2): 100073, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676295
9.
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial.
Ann Oncol;
32(1): 66-76, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33098997
10.
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.
Ann Oncol;
31(1): 30-40, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31912793
11.
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
Clin Transl Oncol;
22(3): 294-301, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31630357
12.
Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.
Int J Cancer;
145(3): 686-693, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30672594
13.
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.
Breast;
41: 165-171, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30103105
14.
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Ann Oncol;
29(1): 112-118, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950295
15.
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Ann Oncol;
28(11): 2906, 2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327895
16.
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Ann Oncol;
28(12): 3110, 2017 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327986
17.
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Ann Oncol;
27(11): 2074-2081, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27573560
18.
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ann Oncol;
27(6): 1055-1061, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27002107
19.
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.
ESMO Open;
1(6): e000086, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28848656
20.
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Ann Oncol;
26(8): 1710-4, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25851630